Repaid
Pharmaceuticals January’25 Series I
Pre-Tax XIRR
14.33%
Tenure
60 Days
Principal & Interest Repayment
On Maturity
Est. Maturity Date
27 Mar 2025
From
India
To
South America
₹25,00,000.00 / ₹25,00,000.00
100% Subscribed
Commodity Highlights
India is a significant player in both the pharmaceutical and polyfilms industries. The pharmaceutical industry is primarily concentrated in Maharashtra, Gujarat, Telangana, and Andhra Pradesh. India's pharmaceutical exports have shown robust growth, with the country exporting billions of dollars annually. Similarly, the polyfilms industry is concentrated in Maharashtra, Gujarat, and Tamil Nadu, with substantial growth in exports, reaching billions of dollars annually.
Trends in the Export of Pharmaceuticals
In the first half of 2023, Indian pharmaceutical exports grew by 18%, reaching $12.4 billion, positioning India among the top exporters globally. The United States, United Kingdom, and South Africa are the top destinations for Indian pharmaceuticals, with exports worth $7.2 billion, $1.4 billion, and $0.9 billion respectively in 2022-23. Meanwhile, Indian polyfilm exports grew by approximately 28% in the first half of 2023, reaching 165 thousand metric tons. This growth enhances India's competitiveness in the global market, with the United States, Germany, and the United Kingdom being the top destinations. The United States is the largest market for Indian polyfilms, with exports worth around $180 million in 2019-20, followed by Germany at $95 million and the United Kingdom at $90 million.
Risk Management
Risk: Delay in arrival of the shipment
Regardless of the delay in the cargo, the borrower is contractually bound to pay the interest for the delayed period
Mitigant: Steady Returns
Regardless of the delay in the cargo, the borrower is contractually bound to pay the interest for the delayed period
Risk: Market volatility
The market risk involves the impact of changing market conditions and broader economic variables on our investments.
Mitigant: Non-Market Linked Instrument
As Precize's Private Credit is a debt instrument, your funds remain sheltered from market volatility, offering stability in varying market conditions.
Risk: Default by the borrower
Credit risk is associated with the possibility of the borrower failing to meet their agreed-upon repayment obligations, encompassing both principal and interest.
Mitigant: Due Diligence
Pazago's seasoned experts use a meticulous selection process to choose the commodities. Additionally rigorous due diligence is conducted on both exporters and importers involved in the trade
FAQs
What is Precize’s Private Credit?
What is XIRR?
What is the minimum investment for this opportunity?
Once the asset is matured, how will I get the principal and interest?
What documentation will serve as a confirmation of my investment?
How can I track my investment?
Is the Interest earned from Private Credit taxable?
Are there any withdrawal fees implied:
Are there any hidden charges?
In case of any further queries, who can I reach out to?
Please read these important legal notices and disclosures
None of the information displayed on or downloadable from https://precize.in represents an offer to buy or sell or a solicitation of an offer to buy or sell any security, nor does it constitute an offer to provide investment advice or service. Registered representatives of precize do not (1) Advise any member on the merits or advisability of a particular investment or transaction, or (2) Assist in the determination of fair value of any security or investment, or (3) Provide legal, tax, or transactional advisory services.